CCL23 (Chemokine (C-C motif) ligand 23)

The dynamic regulation of immune markers in different disease states the use in predicting responses to antifungal treatment, depending on the goal of the assessment. Future studies should validate these biomarkers and establish their usefulness in clinical practice.

This study provides the first high-content proteomic atlas of intrathecal ICI therapy in LM, identifies intrathecal ICI therapy-specific immune remodeling in LM, and establishes a CSF-based predictive model with high accuracy. ADGRG1 represents a promising biomarker of treatment responsiveness and a potential mechanistic link between macrophage biology and LM progression.

The significant increases in serum PDGF-AA and TGF-α, and significant decreases in serum EGF and Flt3 ligand could be explained by post-procedural inflammatory or paraneoplastic mechanisms. Further research into these biomarkers with larger cohorts may enable further understanding of their role pre- and post-operatively in TTPB and their correlation with clinical outcomes. This may be used to develop a clinical tool to predict or identify patients at risk of early post-TTPB complications.

P=N/A, N=137, Completed, National University of Singapore | Recruiting --> Completed | N=200 --> 137 | Trial completion date: Dec 2025 --> May 2025 | Trial primary completion date: Dec 2024 --> Apr 2025

In vitro, CCL23-stimulated THP-1 macrophages exhibited reduced CXCL10 secretion via STAT-3 activation. High CCL23 concentrations in ovarian cancer ascites reduces CXCL10 secretion from myeloid cells and associates with reduced patient survival.

In addition, comparative analyses revealed conserved gene signatures in human basal cell carcinoma of the eyelids, emphasizing the importance of canine models in translational oncology. This comprehensive molecular characterization provides new insights into the pathogenesis of canine eyelid melanoma and identifies key biomarkers and pathways that may be relevant for future therapeutic interventions in veterinary and comparative oncology.

Additionally, C-C motif chemokine Ligand 23 (CCL23) mediated the causal effect of family Porphyromonadaceae on CR-NETs (with a mediation proportion of 6.3%), while C-C motif chemokine Ligand 4 (CCL4) mediated the causal effect of genus Ruminococcaceae NK4A214 group on CR-NETs (with a mediation proportion of 4.7%). There is a causal relationship between gut microbiota and inflammatory proteins in the development of CR-NETs, with CCL23 and CCL4 possibly playing a mediating role.

Additionally, the high- and low-risk groups showed distinct immune infiltration patterns and immune checkpoint expression. Our study established an MIRG-based prognostic risk model that can effectively predict the prognosis of AML patients.

Our results suggest that PFS and OS are negatively affected by elevated CXCL9, CXCL10, and CCL23 levels after CCRT followed by durvalumab treatment. These soluble mediators may be useful tools for the clinical management of locally advanced NSCLC treated with PD-L1 therapy after CCRT.

Stroke disability and severity were associated with inflammation in an indigenous African population. The identified biomarkers might be useful for predicting stroke outcome or serve as therapeutic target.

Our study identifies I-SCORE, derived from plasma proteomics, as a promising integrated biomarker for predicting ICI outcomes in NSCLC. It suggests targeting specific proteins or the associated immunosuppressive microenvironment might enhance immunotherapy efficacy.

This study successfully constructed the correlation between UCN overexpression and immunosuppressive TIME formation in CRC, providing a candidate target for new immunotherapy against CRC development.